Arun Singh, MD, and colleagues developed a model that provides direct diagnostic prediction of a lesion being iris melanoma. He is Director of the Department of Ophthalmic Oncology, Cole Eye Institute at the Cleveland Clinic, Cleveland Clinic Main Campus Hospital, Cleveland.
Melanoma News
Novel immunotherapy combo shows promise in melanoma
Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% of patients with stage 3 cutaneous melanoma, according to the results of a single-arm phase 2 clinical trial led by the University of Pittsburgh, UPMC Hillman Cancer Center and the National Cancer Institute (NCI).
Success in First Real-World Case of Relatlimab Combo for Treatment of Conjunctival Melanoma
With recent interest in immunotherapy on the rise, researchers led by Mirona Attrash treated an older patient presenting with invasive conjunctival melanoma who elected to bypass surgery with the combination of relatlimab-nivolumab (anti-PD-L1/anti-LAG3 inhibitors).
Opdivo and Yervoy May Improve Survival for Resected Stage 3/4 Melanoma
Patients with resected stage 3 or 4 melanoma treated with immune-oncology agents demonstrated significantly higher cure rates compared to those treated with placebo.